Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type 2 (CAV-2), canine parvovirus (CPV), and canine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of six dogs, served as challenge controls. Dogs were kept in strict isolation for 3 years following the vaccination and then challenged sequentially with virulent canine adenovirus type 1 (CAV-1), CPV, and CDV. For each viral challenge, a separate group of six control dogs was also challenged. Clinical signs of CAV-1, CPV, and CDV infections were prevented in 100% of vaccinated dogs, demonstrating that the multivalent, modified-live test vaccine provided protection against virulent CAV-1, CPV, and CDV challenge in dogs 7 weeks of age or older for a minimum of 3 years following second vaccination.
Gore
Thomas C
TC
Intervet Inc, 29160 Intervet Lane, PO Box 318, Millsboro, DE 19966, USA.
Lakshmanan
Nallakannu
N
Duncan
Karen L
KL
Coyne
Michael J
MJ
Lum
Melissa A
MA
Sterner
Frank J
FJ
D000256:Adenoviridae / Q000276:immunology; D000257:Adenoviridae Infections / Q000517:prevention & control / Q000662:veterinary; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004216:Distemper / Q000517:prevention & control; D004217:Distemper Virus, Canine / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D008297:Male; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary; D017993:Parvovirus, Canine / Q000276:immunology; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines
D000914:Antibodies, Viral; D014765:Viral Vaccines